Key facts
- This page summarizes Jeffrey M. Leiden's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
- 16 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Dec 2025, 16:10.
Jeffrey M. Leiden - 03 Dec 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- VRTX
- Reported as of
- 03 Dec 2025
- Net transaction value
- -$23,131,913
- SEC form
- 4
- Accepted by SEC
- 05 Dec 2025, 16:10:39 UTC
- Prior SEC filing
- 17 Nov 2025
- Next SEC filing
- 26 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christiana Stevenson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey M. Leiden filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 05 Dec 2025.
Change
- Previous filing in this sequence was filed on 17 Nov 2025.
- Current net transaction value: -$23,131,913.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001242825
Primary reporting owner
LEIDEN JEFFREY M
- Relationship
- Executive Chairman, Director
- Address
- C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
- Signature
- /s/ Christiana Stevenson, Attorney-in-Fact
- Signature date
- 05 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VRTX
transaction
Common Stock
Options Exercise
- Transaction value
- $5,518,332
- Shares
- +63,781
- Change %
- +265%
- Price
- $86.52
- Shares after
- 87,807
- Date
- 03 Dec 2025
- Ownership
- Direct
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,968,148
- Shares
- -4,469
- Change %
- -5.1%
- Price
- $440.40
- Shares after
- 83,338
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
VRTX
transaction
Common Stock
Sale
- Transaction value
- $582,463
- Shares
- -1,320
- Change %
- -1.6%
- Price
- $441.26
- Shares after
- 82,018
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F4
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,094,285
- Shares
- -2,469
- Change %
- -3%
- Price
- $443.21
- Shares after
- 79,549
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F5
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,933,855
- Shares
- -4,352
- Change %
- -5.5%
- Price
- $444.36
- Shares after
- 75,197
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F6
VRTX
transaction
Common Stock
Sale
- Transaction value
- $3,519,478
- Shares
- -7,899
- Change %
- -11%
- Price
- $445.56
- Shares after
- 67,298
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F7
VRTX
transaction
Common Stock
Sale
- Transaction value
- $515,002
- Shares
- -1,152
- Change %
- -1.7%
- Price
- $447.05
- Shares after
- 66,146
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F8
VRTX
transaction
Common Stock
Sale
- Transaction value
- $1,041,170
- Shares
- -2,320
- Change %
- -3.5%
- Price
- $448.78
- Shares after
- 63,826
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F9
VRTX
transaction
Common Stock
Sale
- Transaction value
- $2,645,059
- Shares
- -5,880
- Change %
- -9.2%
- Price
- $449.84
- Shares after
- 57,946
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F10
VRTX
transaction
Common Stock
Sale
- Transaction value
- $2,621,021
- Shares
- -5,809
- Change %
- -10%
- Price
- $451.20
- Shares after
- 52,137
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F11
VRTX
transaction
Common Stock
Sale
- Transaction value
- $7,090,948
- Shares
- -15,681
- Change %
- -30%
- Price
- $452.20
- Shares after
- 36,456
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F12
VRTX
transaction
Common Stock
Sale
- Transaction value
- $4,696,602
- Shares
- -10,360
- Change %
- -28%
- Price
- $453.34
- Shares after
- 26,096
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F13
VRTX
transaction
Common Stock
Sale
- Transaction value
- $942,305
- Shares
- -2,070
- Change %
- -7.9%
- Price
- $455.22
- Shares after
- 24,026
- Date
- 03 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F14
VRTX
transaction
Common Stock
Options Exercise
- Transaction value
- $91.05
- Shares
- +1
- Change %
- +0%
- Price
- $91.05
- Shares after
- 24,027
- Date
- 04 Dec 2025
- Ownership
- Direct
VRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 440
- Date
- 03 Dec 2025
- Ownership
- 401(k)
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VRTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -63,781
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 63,781
- Exercise price
- $86.52
- Footnotes
- F15
VRTX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 04 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1
- Exercise price
- $91.05
- Footnotes
- F15
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 15 footnotes
Footnote F1
Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.
Footnote F2
Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Footnote F3
Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00).
Footnote F4
Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00).
Footnote F5
Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93).
Footnote F6
Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94).
Footnote F7
Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82).
Footnote F8
Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23).
Footnote F9
Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12).
Footnote F10
Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18).
Footnote F11
Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70).
Footnote F12
Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69).
Footnote F13
Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70).
Footnote F14
Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66).
Footnote F15
Fully vested.